S12 Ep43: Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD
In today’s episode, we had the pleasure of speaking with Nicole Lamanna, MD, about patient selection considerations for the use of pirtobrutinib (Jaypirca) in the management of chronic lymphocytic leukemia (CLL). Dr Lamanna is a hematologic oncologist at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York.
In our exclusive interview, Dr Lamanna discussed how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in patients with CLL. She also…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.